Basisstatistiken
| LEI | 549300UKS15BEXENY615 |
| CIK | 1810560 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Revelation Biosciences, Inc.
SEC Filings (Chronological Order)
Auf dieser Seite finden Sie eine vollständige, chronologische Liste der SEC-Einreichungen, mit Ausnahme der Eigentumseinreichungen, die wir an anderer Stelle bereitstellen.
| June 1, 2026 |
FORM 8-K Item 8.01 Other Information. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 01, 2026 REVELATION BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39603 84-3898466 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| June 1, 2026 |
Exhibit 99.1 |
|
| May 11, 2026 |
Dear Stockholders: As you know, Revelation is a clinical stage company working to develop a high-impact, potentially lifesaving drug called Gemini for the treatment of acute kidney injury (AKI). |
|
| May 11, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| May 7, 2026 |
EXHIBIT 3.1 CERTIFICATE OF AMENDMENT to the THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION of REVELATION BIOSCIENCES, INC. REVELATION BIOSCIENCES, INC., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify as follows: FIRST: The name of the Corporation is Revelation Biosciences, Inc. The Corporation's orig |
|
| May 7, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Classr UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39603 REVELATION BIOSCIENCES, INC. |
|
| May 7, 2026 |
Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026 Exhibit 99.1 Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026 SAN DIEGO – May 7, 2026 – Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today reported its financial results for the three months ended March 31, 2026 |
|
| May 7, 2026 |
FORM 8-K Item 2.02 Results of Operations and Financial Condition. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 07, 2026 REVELATION BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39603 84-3898466 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| April 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| April 15, 2026 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) REVELATION BIOSCIENCES, INC. |
|
| April 15, 2026 |
A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 REVELATION BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 84-3898466 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 4660 La Jolla Village Drive, Suite 100 San Diego, CA 9212 |
|
| April 15, 2026 |
Exhibit 10.1 REVELATION BIOSCIENCES, INC. 2026 EQUITY INDUCEMENT PLAN TABLE OF CONTENTS 1. Purpose of Plan. 1 2. Definitions. 1 3. Plan Administration. 6 4. Shares Available for Issuance. 8 5. Participation. 9 6. Options. 9 7. Restricted Stock Awards and Restricted Stock Units. 10 8. Performance Awards. 12 9. Other Stock-Based Awards. 13 10. Dividend Equivalents. 14 11. Effect of Termination of Em |
|
| April 15, 2026 |
NOTICE OF NON-PLAN EMPLOYEE INDUCEMENT RESTRICTED STOCK UNIT GRANT Exhibit 10.2 NOTICE OF NON-PLAN EMPLOYEE INDUCEMENT RESTRICTED STOCK UNIT GRANT Revelation Biosciences, Inc., a Delaware corporation (the “Company”), hereby grants to the new employee of the Company named below (the “Participant”) the number of Restricted Stock Units (as defined below) as set forth below. The award of Restricted Stock Units is intended to constitute an employment inducement award |
|
| March 19, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2026 REVELATION BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39603 84-3898466 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 26, 2026 |
CLASS J COMMON STOCK PURCHASE WARRANT Revelation Biosciences, Inc. Exhibit 4.18 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| February 26, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K r UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39603 REVELATION BIOSCIENCES, INC. |
|
| February 26, 2026 |
Exhibit 99.1 Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025 SAN DIEGO – February 26, 2026 – Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, today reported its financial results for the three and twelve months e |
|
| February 26, 2026 |
Exhibit 10.12 revelation biosciences, inc. January 23, 2026 Holder of Common Stock Purchase Warrants Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: Revelation Biosciences, Inc. (the “Company”) is pleased to offer to you (“Holder”, “you” or similar terminology) (i) the opportunity to receive new warrants to purchase shares of the Company’s common stock, par value $0.00 |
|
| February 26, 2026 |
DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT EXHIBIT 4.19 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT Authorized and Outstanding Stock The Charter authorizes the issuance of an aggregate of 505,000,000 shares of capital stock, consisting of 500,000,000 shares of common stock, $0.001 par value per share and 5,000,000 shares of preferred stock, $0.001 par value per share. The outstanding shares of common stock are |
|
| February 26, 2026 |
FORM 8-K Item 2.02 Results of Operations and Financial Condition. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 06, 2025 REVELATION BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39603 84-3898466 (State or Other Jurisdiction of Incorporation) (Com |
|
| February 17, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| February 11, 2026 |
As filed Pursuant to Rule 424(b)(3) Registration No. 333-293078 PROSPECTUS Revelation Biosciences, Inc. 4,272,500 Shares of Common Stock This prospectus relates to the resale, from time to time, of up to 4,272,500 shares of common stock, par value $0.001 per share, by the selling stockholders identified in this prospectus under “Selling Stockholders” (the “Selling Stockholders”) to be issued upon |
|
| February 9, 2026 |
Revelation Biosciences, Inc. 4660 La Jolla Village Drive, Suite 100 San Diego, California 92122 Revelation Biosciences, Inc. 4660 La Jolla Village Drive, Suite 100 San Diego, California 92122 February 9, 2026 VIA EDGAR AND E-MAIL Mr. Chris Edwards Office of Life Sciences Division of Corporate Finance U.S. Securities and Exchange Commission 100 F Street, NE Washington, DC 20549-7010 Re: Revelation Biosciences, Inc. Registration Statement on Form S-3 Commission File No. 333-293078 Dear Mr. Edw |
|
| February 6, 2026 |
February 6, 2026 James Rolke Chief Executive Officer Revelation Biosciences, Inc. 4660 La Jolla Village Drive, Suite 100 San Diego, California 92122 Re: Revelation Biosciences, Inc. Registration Statement on Form S-3 Filed January 30, 2026 File No. 333-293078 Dear James Rolke: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 |
|
| February 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| January 30, 2026 |
As filed with the Securities and Exchange Commission on January 30, 2026 Registration No. |
|
| January 30, 2026 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-3 (Form Type) REVELATION BIOSCIENCES, INC. |
|
| January 29, 2026 |
CLASS J COMMON STOCK PURCHASE WARRANT Revelation Biosciences, Inc. Exhibit 10.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| January 29, 2026 |
EXHIBIT A EXISTING WARRANTS EXHIBIT B FORM OF NEW WARRANT Exhibit 4.1 revelation biosciences, inc. January 23, 2026 Holder of Common Stock Purchase Warrants Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: Revelation Biosciences, Inc. (the “Company”) is pleased to offer to you (“Holder”, “you” or similar terminology) (i) the opportunity to receive new warrants to purchase shares of the Company’s common stock, par value $0.001 |
|
| January 29, 2026 |
FORM 8-K Item 1.01 Entry into a Material Definitive Agreement. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2026 REVELATION BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39603 84-3898466 (State or Other Jurisdiction of Incorporation) (Comm |
|
| January 22, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2026 REVELATION BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39603 84-3898466 (State or Other Jurisdiction of Incorporation) (Comm |
|
| January 22, 2026 |
Exhibit 99.2 |
|
| January 22, 2026 |
Exhibit 99.1 Revelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKI - Single Phase 2/3 Adaptive Study Design - - Clinically Relevant, Objective Composite Endpoint - SAN DIEGO, CA - January 21, 2026 - Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation, announced |
|
| December 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 03, 2025 REVELATION BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39603 84-3898466 (State or Other Jurisdiction of Incorporation) (Com |
|
| December 3, 2025 |
Transcript of Corporate Update December 3, 2025 Exhibit 99.1 Transcript of Corporate Update December 3, 2025 Before we end the call, I would like to take a minute or two to provide a brief corporate update and to reflect on 2025. During 2025, we as a Company met our primary corporate objectives and have conducted and completed a Phase 1b clinical study in CKD patients, where we generated some really fantastic game changing results where we were |
|
| November 12, 2025 |
Exhibit 5.01 November 12, 2025 Revelation Biosciences, Inc. 4660 La Jolla Village Drive, Suite 100 San Diego, California 92122 Re: Revelation Biosciences, Inc. Registration Statement on Form S-8 Ladies and Gentlemen: We have acted as counsel to Revelation Biosciences, Inc., a Delaware corporation (the “Company”), in connection with the Company’s registration of an aggregate of 4,647,222 shares (co |
|
| November 12, 2025 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 23.01 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in this Registration Statement on Form S-8 of Revelation Biosciences, Inc. (the “Company”) of our report dated March 6, 2025 relating to the consolidated financial statements of Revelation Biosciences, Inc., as of and for the years ended December 31, 2024 and 2023, which includes an |
|
| November 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 REVELATION BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 84-3898466 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 4660 La Jolla Village Drive, Suite 100 San Diego, CA 92122 |
|
| November 12, 2025 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) REVELATION BIOSCIENCES, INC. |
|
| November 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| November 6, 2025 |
FORM 8-K Item 2.02 Results of Operations and Financial Condition. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 06, 2025 REVELATION BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39603 84-3898466 (State or Other Jurisdiction of Incorporation) (Com |
|
| November 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Classr UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39603 REVELATION BIOSCIENCES, INC. |
|
| November 6, 2025 |
Exhibit 99.1 Revelation Biosciences, Inc. Announces Financial Results for the three and nine months ended September 30, 2025 San Diego, CA – November 6, 2025 – Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its financial results for the three and nine |
|
| October 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| October 29, 2025 |
Revelation Biosciences Inc. Announces Cancellation of Adjournment of October 29, 2025 Special Meeting of Stockholders and New Record Date San Diego, CA, October 29, 2025 – Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company focused on rebalancing inflammation, announced today the October 15, 2025 Special Meeting of Stockholders of Rev |
|
| October 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2025 REVELATION BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39603 84-3898466 (State or Other Jurisdiction of Incorporation) (Comm |
|
| October 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2025 REVELATION BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39603 84-3898466 (State or Other Jurisdiction of Incorporation) (Comm |
|
| October 15, 2025 |
Revelation Biosciences Inc. Announces Adjournment of October 15, 2025 Special Meeting of Stockholders to October 29, 2025 San Diego, CA, October 15, 2025 – Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company focused on rebalancing inflammation, today announced that the Company as a result of insufficient shares present it has adjourne |
|
| September 30, 2025 |
As filed with the Securities and Exchange Commission on September 30, 2025 Registration No. |
|
| September 30, 2025 |
X0101 EFFECT 33 LIVE 2025-09-30 17:00:00 S-3 0001810560 REVELATION BIOSCIENCES, INC. 333-290309 |
|
| September 30, 2025 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-3 (Form Type) REVELATION BIOSCIENCES, INC. |
|
| September 30, 2025 |
As filed Pursuant to Rule 424(b)(3) Registration No. 333-290309 PROSPECTUS Revelation Biosciences, Inc. 13,065,000 Shares of Common Stock This prospectus relates to the resale, from time to time, of up to 13,065,000 shares of common stock, par value $0.001 per share, by the selling stockholders identified in this prospectus under “Selling Stockholders” (the “Selling Stockholders”) to be issued upo |
|
| September 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| September 16, 2025 |
As filed with the Securities and Exchange Commission on September 16, 2025 Registration No. |
|
| September 16, 2025 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-3 (Form Type) REVELATION BIOSCIENCES, INC. |
|
| September 15, 2025 |
EXHIBIT A EXISTING WARRANTS EXHIBIT B FORM OF NEW WARRANT revelation biosciences, inc. September 10, 2025 Holder of Common Stock Purchase Warrants Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: Revelation Biosciences, Inc. (the “Company”) is pleased to offer to you (“Holder”, “you” or similar terminology) (i) the opportunity to receive new warrants to purchase shares of the Company’s common stock, par value $0.001 per share |
|
| September 15, 2025 |
Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds San Diego, CA, September 11, 2025 – Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company focused on rebalancing inflammation, announced today the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to p |
|
| September 15, 2025 |
CLASS I COMMON STOCK PURCHASE WARRANT Revelation Biosciences, Inc. NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. |
|
| September 15, 2025 |
FORM 8-K Item 1.01 Entry into a Material Definitive Agreement. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2025 REVELATION BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39603 84-3898466 (State or Other Jurisdiction of Incorporation) (Co |
|
| September 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| September 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 09, 2025 REVELATION BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39603 84-3898466 (State or Other Jurisdiction of Incorporation) (Co |
|
| September 9, 2025 |
Revelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical Study – Gemini normalized the inflammatory response at the cellular level in stage 3 and 4 CKD patients – – Gemini could potentially revolutionize the treatment of acute and chronic inflammatory disease – Data discussion webcast/conference call will be held on Wednesday, September 10th at 8:30 am Eastern Time San Diego, CA – September 9, 2025 – Revelation Biosciences, Inc. |
|
| September 9, 2025 | ||
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q r UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39603 REVELATION BIOSCIENCES, INC. |
|
| August 8, 2025 |
Exhibit 99.1 Revelation Biosciences, Inc. Announces Financial Results for the three and six months ended June 30, 2025 San Diego, CA – August 8, 2025 – Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its financial results for the three and six months en |
|
| August 8, 2025 |
FORM 8-K Item 2.02 Results of Operations and Financial Condition. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 08, 2025 REVELATION BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39603 84-3898466 (State or Other Jurisdiction of Incorporation) (Commi |
|
| July 9, 2025 |
Amendment to the Third Amended and Restated Certificate of Incorporation effective July 7, 2025 EXHIBIT 3.1 CERTIFICATE OF AMENDMENT to the THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION of REVELATION BIOSCIENCES, INC. REVELATION BIOSCIENCES, INC., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify as follows: FIRST: The name of the Corporation is Revelation Biosciences, Inc. The Corporation’s orig |
|
| July 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 07, 2025 REVELATION BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39603 84-3898466 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| July 9, 2025 |
Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split effective July 7, 2025 Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split effective July 7, 2025 San Diego, CA – July 1, 2025 – Revelation Biosciences, Inc.(NASDAQ: REVB) (the “Company” or “Revelation”), announced today that, on July 7, 2025, the Company will implement a 1-for-3 reverse split of its common stock following approval at its Special Meeting of Stockholders held on June 23, 2025. The reverse s |
|
| June 25, 2025 | ||
| June 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2025 REVELATION BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39603 84-3898466 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| June 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| June 4, 2025 |
Revelation Biosciences, Inc. Announces Pricing of $4 Million Public Offering Exhibit 99.1 Revelation Biosciences, Inc. Announces Pricing of $4 Million Public Offering San Diego, CA – May 29, 2025 – Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today announced the pricing of a public offering of 3,640,000 shares of its common stock (or common |
|
| June 4, 2025 |
Form of Pre-Funded Common Stock Warrant Exhibit 4.2 PRE-FUNDED COMMON STOCK PURCHASE WARRANT Revelation Biosciences, Inc. Warrant Shares: [*] Initial Exercise Date: May 29, 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [*] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or |
|
| June 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2025 REVELATION BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39603 84-3898466 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| June 4, 2025 |
Form of Securities Purchase Agreement Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 28, 2025, between Revelation Biosciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditi |
|
| June 4, 2025 |
Warrant Agency Agreement dated May 28, 2025 Exhibit 4.1 Revelation Biosciences, Inc. and Continental Stock Transfer & Trust Company as Warrant Agent Warrant Agency Agreement Dated as of May 29, 2025 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of May 29, 2025 (“Agreement”), between Revelation Biosciences, Inc., a Delaware corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation (the |
|
| June 4, 2025 |
Placement Agency Agreement dated May 28, 2025 Exhibit 10.1 PLACEMENT AGENCY AGREEMENT May 28, 2025 Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Revelation Biosciences, Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $4,004,000 of registered securities of the Compan |
|
| June 4, 2025 |
Form of Class H Common Stock Warrant Exhibit 4.3 CLASS H COMMON STOCK PURCHASE WARRANT Revelation Biosciences, Inc. Warrant Shares: 14,560,000 Issue Date: May 29, 2025 CUSIP: 76135L168 ISIN: US76135L1686 THIS CLASS H COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, CEDE & CO. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereina |
|
| June 4, 2025 |
Revelation Biosciences, Inc. Announces Closing of $4 Million Public Offering Exhibit 99.2 Revelation Biosciences, Inc. Announces Closing of $4 Million Public Offering San Diego, CA – May 29, 2025 – Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today announced the closing of its previously announced public offering of 3,640,000 shares of its |
|
| May 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| May 29, 2025 |
Rule 424(b)(3) Commission File No. 333-287423 PROSPECTUS REVELATION BIOSCIENCES, INC. 675,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 2,965,000 Shares of Common Stock and 2,965,000 Shares of Common Stock Underlying the Pre-Funded Warrants 14,560,000 Class H Common Stock Warrants to Purchase 14,560,000 Shares of Common Stock and 14,560,000 Shares of Common Stock Underlying the |
|
| May 28, 2025 |
Revelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of Directors Revelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of Directors San Diego, CA – May 23, 2025 – Revelation Biosciences, Inc. |
|
| May 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2025 REVELATION BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39603 84-3898466 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 23, 2025 |
Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2025, between Revelation Biosciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions se |
|
| May 23, 2025 |
J.P. Galda & Co. 40 East Montgomery Avenue, LTW 220 Ardmore, Pennsylvania 19008 J.P. Galda & Co. 40 East Montgomery Avenue, LTW 220 Ardmore, Pennsylvania 19008 May 23, 2025 VIA EDGAR AND E-MAIL Mr. Alan Campbell Mr. Joseph McCann Office of Life Sciences Division of Corporate Finance U.S. Securities and Exchange Commission 100 F. Street, N.E. Washington, DC 20549-7010 Re: Revelation Biosciences, Inc. Registration Statement on Form S-1 Commission File No. 333-287423 Gentlemen: |
|
| May 23, 2025 |
Exhibit 107 FILING FEE TABLES FOR FORM S-1 Calculation of Filing Fee Tables Form S-1 (Form Type) REVELATION BIOSCIENCES, INC. |
|
| May 23, 2025 |
As filed with the U.S. Securities and Exchange Commission on May 23, 2025 As filed with the U.S. Securities and Exchange Commission on May 23, 2025 Registration No. 333-287423 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 REVELATION BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) DELAWARE (Jurisdiction of incorporation or organization) 2 |
|
| May 23, 2025 |
Form of Warrant Agency Agreement with Continental Stock Transfer & Trust Co. Exhibit 4.18 Revelation Biosciences, Inc. and Continental Stock Transfer & Trust Company as Warrant Agent Warrant Agency Agreement Dated as of , 2025 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of , 2025 (“Agreement”), between Revelation Biosciences, Inc., a Delaware corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation (the “Warrant Ag |
|
| May 23, 2025 |
Form of Class H Common Stock Warrant Exhibit 4.16 EXHIBIT A-1 CLASS H COMMON STOCK PURCHASE WARRANT Revelation Biosciences, Inc. Warrant Shares: Issue Date: , 2025 CUSIP: ISIN: THIS CLASS H COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or afte |
|
| May 22, 2025 |
REVELATION BIOSCIENCES, INC. 4660 La Jolla Village Drive, Suite 100 San Diego, CA 92122 REVELATION BIOSCIENCES, INC. 4660 La Jolla Village Drive, Suite 100 San Diego, CA 92122 May 22, 2025 VIA EDGAR AND E-MAIL Mr. Alan Campbell Office of Life Sciences Division of Corporate Finance U.S. Securities and Exchange Commission 100 F. Street, N.E. Washington, DC 20549-7010 Re: Revelation Biosciences Inc. Registration Statement on Form S-1; Commission File No. 333-287423 Dear Mr. Campbell: In |
|
| May 22, 2025 |
REVELATION BIOSCIENCES, INC. 4660 La Jolla Village Drive, Suite 100 San Diego, CA 92122 REVELATION BIOSCIENCES, INC. 4660 La Jolla Village Drive, Suite 100 San Diego, CA 92122 May 22, 2025 VIA EDGAR AND E-MAIL Mr. Alan Campbell Office of Life Sciences Division of Corporate Finance U.S. Securities and Exchange Commission 100 F. Street, N.E. Washington, DC 20549-7010 Re: Revelation Biosciences, Inc. Registration Statement on Form S-1; Commission File No. 333-287423 Dear Mr. Campbell: P |
|
| May 21, 2025 |
May 21, 2025 James Rolke Chief Executive Officer Revelation Biosciences, Inc. 4660 La Jolla Village Drive, Suite 100 San Diego, CA 92122 Re: Revelation Biosciences, Inc. Registration Statement on Form S-1 Filed May 20, 2025 File No. 333-287423 Dear James Rolke: We have conducted a limited review of your registration statement and have the following comments. Please respond to this letter by amendi |
|
| May 20, 2025 |
Form of Class H-1 Common Stock Warrant Exhibit 4.16 EXHIBIT A-1 CLASS H-1 COMMON STOCK PURCHASE WARRANT Revelation Biosciences, Inc. Warrant Shares: Issue Date: , 2025 CUSIP: ISIN: THIS CLASS H-1 COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or |
|
| May 20, 2025 |
Exhibit 4.19 PRE-FUNDED COMMON STOCK PURCHASE WARRANT Revelation Biosciences, Inc. Warrant Shares: Initial Exercise Date: February 5, 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or af |
|
| May 20, 2025 |
Exhibit 107 FILING FEE TABLES FOR FORM S-1 Calculation of Filing Fee Tables Form S-1 (Form Type) REVELATION BIOSCIENCES, INC. |
|
| May 20, 2025 |
Form of Warrant Agency Agreement with Continental Stock Transfer & Trust Co. Exhibit 4.20 Revelation Biosciences, Inc. and Continental Stock Transfer & Trust Company as Warrant Agent Warrant Agency Agreement Dated as of , 2025 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of , 2025 (“Agreement”), between Revelation Biosciences, Inc., a Delaware corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation (the “Warrant Ag |
|
| May 20, 2025 |
Form of Class H-3 common Stock Warrant Exhibit 4.18 EXHIBIT A-1 CLASS H-3 COMMON STOCK PURCHASE WARRANT Revelation Biosciences, Inc. Warrant Shares: Issue Date: , 2025 CUSIP: ISIN: THIS CLASS H-3 COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or |
|
| May 20, 2025 |
Exhibit 10.2 LOCK-UP AGREEMENT , 2025 Revelation Biosciences, Inc. Roth Capital Partners, LLC, as placement agent in the Offering (as defined below) Re: Offering (as defined below) by Revelation Biosciences, Inc. (the “Company”) Ladies and Gentlemen: The undersigned irrevocably agrees with the Company that, from the date hereof until ninety (90) days following the closing of the Company’s offering |
|
| May 20, 2025 |
REVELATION BIOSCIENCES, INC. 4660 La Jolla Village Drive, Suite 100 San Diego, CA 92122 REVELATION BIOSCIENCES, INC. 4660 La Jolla Village Drive, Suite 100 San Diego, CA 92122 May 20, 2025 VIA EDGAR AND E-MAIL Mr. Allan Campbell Office of Life Sciences Division of Corporate Finance U.S. Securities and Exchange Commission 100 F. Street, N.E. Washington, DC 20549-7010 Re: Revelation Biosciences Inc. Registration Statement on Form S-1; Commission File No. 333-287423 Dear Mr.Campbell: Pu |
|
| May 20, 2025 |
Form of Class H-2 Common Stock Warrant Exhibit 4.17 EXHIBIT A-1 CLASS H-2 COMMON STOCK PURCHASE WARRANT Revelation Biosciences, Inc. Warrant Shares: Issue Date: , 2025 CUSIP: ISIN: THIS CLASS H-2 COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or |
|
| May 20, 2025 |
As filed with the U.S. Securities and Exchange Commission on May 20, 2025 As filed with the U.S. Securities and Exchange Commission on May 20, 2025 Registration No. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 REVELATION BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) DELAWARE (Jurisdiction of incorporation or organization) 2834 84-3898466 (Primary Standa |
|
| May 20, 2025 |
Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2025, between Revelation Biosciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions se |
|
| May 20, 2025 |
Form of Placement Agency Agreement with Roth Capital Partners, LLC Exhibit 10.3 PLACEMENT AGENCY AGREEMENT , 2025 Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Revelation Biosciences, Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $ of registered securities of the Company, including, b |
|
| May 8, 2025 |
Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025 Exhibit 99.1 Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025 San Diego, CA – May 8, 2025 – Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its three months ended March 31, 2025 financial results. Corpor |
|
| May 8, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2025 REVELATION BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39603 84-3898466 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q r UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39603 REVELATION BIOSCIENCES, INC. |
|
| April 9, 2025 |
April 9, 2025 James Rolke Chief Executive Officer Revelation Biosciences, Inc. 4660 La Jolla Village Drive, Suite 100 San Diego, CA 92122 Re: Revelation Biosciences, Inc. Draft Registration Statement on Form S-1 Submitted April 4, 2025 CIK No. 0001810560 Dear James Rolke: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your regis |
|
| April 4, 2025 |
PLACEMENT AGENCY AGREEMENT ______, 2025 Exhibit 10.3 PLACEMENT AGENCY AGREEMENT , 2025 Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Revelation Biosciences, Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $ of registered securities of the Company, including, b |
|
| April 4, 2025 |
PRE-FUNDED COMMON STOCK PURCHASE WARRANT Revelation Biosciences, Inc. Exhibit 4.17 PRE-FUNDED COMMON STOCK PURCHASE WARRANT Revelation Biosciences, Inc. Warrant Shares: Initial Exercise Date: February 5, 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or af |
|
| April 4, 2025 |
CLASS H COMMON STOCK PURCHASE WARRANT Revelation Biosciences, Inc. Exhibit 4.16 CLASS H COMMON STOCK PURCHASE WARRANT Revelation Biosciences, Inc. Warrant Shares: Initial Exercise Date: , 2025 CUSIP: ISIN: THIS CLASS H COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after |
|
| April 4, 2025 |
Confidentially submitted to the Securities and Exchange Commission on April 4, 2025. |
|
| April 4, 2025 |
Exhibit 4.18 Revelation Biosciences, Inc. and Continental Stock Transfer & Trust Company as Warrant Agent Warrant Agency Agreement Dated as of , 2025 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of , 2025 (“Agreement”), between Revelation Biosciences, Inc., a Delaware corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation (the “Warrant Ag |
|
| April 4, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2025, between Revelation Biosciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions se |
|
| April 4, 2025 |
Exhibit 10.2 LOCK-UP AGREEMENT , 2025 Revelation Biosciences, Inc. Roth Capital Partners, LLC, as placement agent in the Offering (as defined below) Re: Offering (as defined below) by Revelation Biosciences, Inc. (the “Company”) Ladies and Gentlemen: The undersigned irrevocably agrees with the Company that, from the date hereof until ninety (90) days following the closing of the Company’s offering |
|
| March 17, 2025 |
Gemini priming attenuates inflammation in human peripheral blood mononuclear cells – Observed response is excellent surrogate of the potential of Gemini in target indications – – Equivalent response anticipated in Phase 1b study CKD patients – San Diego, CA – March 17, 2025 – Revelation Biosciences, Inc. |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2025 REVELATION BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39603 84-3898466 (State or Other Jurisdiction of Incorporation) (Commis |
|
| March 17, 2025 | ||
| March 6, 2025 |
Exhibit 14.2 INSIDER TRADING POLICY (dated January 10, 2021) I. INTRODUCTION Federal and state laws prohibit buying, selling or making other transfers of securities by persons who have material information that is not generally known or available to the public. These laws also prohibit persons with such material nonpublic information from disclosing this information to others who trade. Revelation |
|
| March 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K r UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39603 REVELATION BIOSCIENCES, INC. |
|
| March 6, 2025 |
Exhibit 99.1 Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024 San Diego, CA – March 6, 2025 – Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its three and twelve months ended December 31, |
|
| March 6, 2025 |
EXHIBIT 4.16 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT Authorized and Outstanding Stock The Charter authorizes the issuance of an aggregate of 505,000,000 shares of capital stock, consisting of 500,000,000 Shares of Common Stock, $0.001 par value per share and 5,000,000 shares of preferred stock, $0.001 par value per share. The outstanding Shares of Common Stock are |
|
| March 6, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 06, 2025 REVELATION BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39603 84-3898466 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 24, 2025 |
Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval EXHIBIT 99.1 Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval San Diego, CA – February 24, 2025 – Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced today the Nasdaq Stock Market LLC (“Nasdaq”) formally notified the Company that REVB comm |
|
| February 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2025 REVELATION BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39603 84-3898466 (State or Other Jurisdiction of Incorporation) (Com |
|
| February 11, 2025 |
Rebalancing inflammation to optimize health NASDAQ: REVB www.revbiosciences.com Rebalancing inflammation to optimize health NASDAQ: REVB www.revbiosciences.com This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words "anticipate", "believe", "expect", "estima |
|
| February 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2025 REVELATION BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39603 84-3898466 (State or Other Jurisdiction of Incorporation) (Com |
|
| January 30, 2025 |
Amendment to the Third Amended and Restated Certificate of Incorporation effective January 28, 2025 EXHIBIT 3.1 CERTIFICATE OF AMENDMENT to the THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION of REVELATION BIOSCIENCES, INC. REVELATION BIOSCIENCES, INC., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify as follows: FIRST: The name of the Corporation is Revelation Biosciences, Inc. The Corporation’s orig |
|
| January 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2025 REVELATION BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39603 84-3898466 (State or Other Jurisdiction of Incorporation) (Comm |
|
| January 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2025 REVELATION BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39603 84-3898466 (State or Other Jurisdiction of Incorporation) (Comm |
|
| January 21, 2025 |
Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients – Dosing to Commence Mid-February – – Topline data expected Mid-Year – San Diego, CA – January 21, 2025 – Revelation Biosciences, Inc. |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuit to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for the use of the Commission only (as permitted by Rule 14a-6(e)(2)) ☐ De |
|
| January 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 03, 2025 REVELATION BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39603 84-3898466 (State or Other Jurisdiction of Incorporation) (Comm |
|
| January 7, 2025 |
Nasdaq Grants Revelation Biosciences Inc. Continued Listing Exhibit 99.1 Nasdaq Grants Revelation Biosciences Inc. Continued Listing San Diego, CA – January 6, 2025 – Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of disease, announced today that the Nasdaq Hearings Panel issued a decision letter granting Revela |
|
| December 20, 2024 |
Revelation Biosciences, Inc. 14,224,140 Shares of Common Stock As filed Pursuant to Rule 424(b)(3) Registration No. 333-283764 PROSPECTUS Revelation Biosciences, Inc. 14,224,140 Shares of Common Stock This prospectus relates to the resale, from time to time, of up to 14,224,140 shares of common stock, par value $0.001 per share, by the selling stockholders identified in this prospectus under “Selling Stockholders” (the “Selling Stockholders”) to be issued upo |
|
| December 20, 2024 |
Revelation Biosciences, Inc. 4660 La Jolla Village Drive, Suite 100 San Diego, California 92122 Revelation Biosciences, Inc. 4660 La Jolla Village Drive, Suite 100 San Diego, California 92122 December 20, 2024 Via EDGAR Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Attention: Chris Edwards Re: Revelation Biosciences, Inc. Registration Statement on Form S-3 Commission File No. 333-283764 Mr. Edwards: On behalf of Revelation Biosciences, Inc. (the “Company”), I hereb |
|
| December 19, 2024 |
As filed with the Securities and Exchange Commission on December 19, 2024 As filed with the Securities and Exchange Commission on December 19, 2024 Registration No. |
|
| December 19, 2024 |
Revelation Biosciences, Inc. 4660 La Jolla Village Drive, Suite 100 San Diego, California 92122 Revelation Biosciences, Inc. 4660 La Jolla Village Drive, Suite 100 San Diego, California 92122 December 19, 2024 Via EDGAR Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Attention: Chris Edwards Re: Revelation Biosciences, Inc. Registration Statement on Form S-3 Commission File No. 333-283764 Mr. Edwards: On behalf of Revelation Biosciences, Inc. (the “Company”), I hereb |
|
| December 18, 2024 |
December 18, 2024 James Rolke Chief Executive Officer Revelation Biosciences, Inc. |
|
| December 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| December 12, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2024 REVELATION BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39603 84-3898466 (State or Other Jurisdiction of Incorporation) (Com |
|
| December 12, 2024 |
As filed with the Securities and Exchange Commission on December 12, 2024 As filed with the Securities and Exchange Commission on December 12, 2024 Registration No. |
|
| December 12, 2024 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-3 (Form Type) REVELATION BIOSCIENCES, INC. |
|
| December 6, 2024 |
Form of Class F Common Stock Warrant dated December 3, 2024 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| December 6, 2024 |
Form of Class G Common Stock Warrant dated December 3, 2024 Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| December 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 03, 2024 REVELATION BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39603 84-3898466 (State or Other Jurisdiction of Incorporation) (Com |
|
| December 6, 2024 |
Exhibit 10.1 revelation biosciences, inc. December 3, 2024 Holder of Common Stock Purchase Warrants Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: Revelation Biosciences, Inc. (the “Company”) is pleased to offer to you (“Holder”, “you” or similar terminology) (i) the opportunity to receive new warrants to purchase shares of the Company’s common stock, par value $0.001 |
|
| December 6, 2024 |
Exhibit 99.1 Revelation Biosciences Inc. Announces FDA Acceptance of Gemini IND -Phase 1b Study in CKD Patients to begin early 2025- San Diego, CA – December 2, 2024 – Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of disease, announced today that the U |
|
| December 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| November 8, 2024 |
Exhibit 99.1 Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024 San Diego, CA – November 8, 2024 – Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and treatment of disease by developing and commer |
|
| November 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 08, 2024 REVELATION BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39603 84-3898466 (State or Other Jurisdiction of Incorporation) (Com |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39603 REVELATION BIOSCIENCES, INC. |
|
| October 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2024 REVELATION BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39603 84-3898466 (State or Other Jurisdiction of Incorporation) (Comm |
|
| September 27, 2024 |
Revelation Biosciences’ Gemini Induces Dose Dependent Significant Increases in IL-10 Exhibit 99.1 Revelation Biosciences’ Gemini Induces Dose Dependent Significant Increases in IL-10 San Diego, CA – September 24, 2024 – Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced statistically significant, d |
|
| September 27, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 24, 2024 REVELATION BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39603 84-3898466 (State or Other Jurisdiction of Incorporation) (Co |
|
| September 25, 2024 |
September 25, 2024 Chester S. Zygmont, III Chief Financial Officer Revelation Biosciences, Inc. 4660 La Jolla Village Drive Suite 100 San Diego, CA 92122 Re: Revelation Biosciences, Inc. Form 10-K for the Fiscal Year Ended December 31, 2023 Filed March 22, 2024 File No. 001-39603 Dear Chester S. Zygmont III: We have completed our review of your filings. We remind you that the company and its manag |
|
| September 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No. |
|
| September 23, 2024 |
J.P. Galda & Co. Attorneys-at-Law 40 E Montgomery Avenue, LTW 220 Ardmore, Pennsylvania 19003 Telephone (215) 815-1534 September 23, 2024 Via Email and EDGAR Office of Life Sciences Division of Corporation Finance Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Attention: Gary Newberry Angela Connell Re: Revelation Biosciences, Inc. Form 10-K for the Fiscal Year Ended Dece |
|
| September 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A (Amendment No. 1) ageord UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A (Amendment No. |
|
| September 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No. |
|
| September 13, 2024 |
Revelation Biosciences, Inc. 5,096,120 Shares of Common Stock As filed Pursuant to Rule 424(b)(3) Registration No. 333-281909 PROSPECTUS Revelation Biosciences, Inc. 5,096,120 Shares of Common Stock This prospectus relates to the resale, from time to time, of up to 5,096,120 shares of common stock, par value $0.001 per share, by the selling stockholders identified in this prospectus under “Selling Stockholders” (the “Selling Stockholders”) to be issued upon |
|
| September 13, 2024 |
September 13, 2024 Chester S. Zygmont, III Chief Financial Officer Revelation Biosciences, Inc. 4660 La Jolla Village Drive Suite 100 San Diego, CA 92122 Re: Revelation Biosciences, Inc. Form 10-K for the Fiscal Year Ended December 31, 2023 Filed March 22, 2024 File No. 001-39603 Dear Chester S. Zygmont III: We have limited our review of your filing to the financial statements and related disclosu |
|
| September 10, 2024 |
Revelation Biosciences, Inc. 4660 La Jolla Village Drive, Suite 100 San Diego, California 92122 Revelation Biosciences, Inc. 4660 La Jolla Village Drive, Suite 100 San Diego, California 92122 September 10, 2024 Via EDGAR Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Attention: Chris Edwards Re: Revelation Biosciences, Inc. Registration Statement on Form S-3 Commission File No. 333-281909 Mr. Edwards: On behalf of Revelation Biosciences, Inc. (the “Company”), I here |
|
| September 9, 2024 |
September 9, 2024 James Rolke Chief Executive Officer Revelation Biosciences, Inc. |
|
| September 3, 2024 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-3 (Form Type) REVELATION BIOSCIENCES, INC. |
|
| September 3, 2024 |
As filed with the Securities and Exchange Commission on September 3, 2024 As filed with the Securities and Exchange Commission on September 3, 2024 Registration No. |
|
| August 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2024 REVELATION BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39603 84-3898466 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 26, 2024 |
Exhibit 10.1 revelation biosciences, inc. August 21, 2024 Holder of Common Stock Purchase Warrants Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: Revelation Biosciences, Inc. (the “Company”) is pleased to offer to you (“Holder”, “you” or similar terminology) (i) the opportunity to receive new warrants to purchase shares of the Company’s common stock, par value $0.0001 |
|
| August 26, 2024 |
Form of Class E Common Stock Warrant dated August 22, 2024 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| August 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 REVELATION BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39603 84-3898466 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39603 REVELATION BIOSCIENCES, INC. |
|
| August 9, 2024 |
Exhibit 99.1 Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2024 San Diego, CA – August 9, 2024 – Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and treatment of disease by developing and commercializin |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 09, 2024 REVELATION BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39603 84-3898466 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 2, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 01, 2024 REVELATION BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39603 84-3898466 (State or Other Jurisdiction of Incorporation) (Commi |
|
| July 23, 2024 |
Revelation Biosciences, Inc. 4660 La Jolla Village Drive, Suite 100 San Diego, California 92122 Revelation Biosciences, Inc. 4660 La Jolla Village Drive, Suite 100 San Diego, California 92122 July 26, 2024 Via EDGAR Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Attention: Chris Edwards Re: Revelation Biosciences, Inc. Registration Statement on Form S-3 Commission File No. 333-280908 Mr. Edwards: On behalf of Revelation Biosciences, Inc. (the “Company”), I hereby re |
|
| July 23, 2024 |
July 23, 2024 James Rolke Chief Executive Officer Revelation Biosciences, Inc. 4660 La Jolla Village Drive, Suite 100 San Diego, California 92122 Re: Revelation Biosciences, Inc. Registration Statement on Form S-3 Filed July 19, 2024 File No. 333-280908 Dear James Rolke: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 4 |
|
| July 19, 2024 |
As filed with the Securities and Exchange Commission on July 19, 2024 As filed with the Securities and Exchange Commission on July 19, 2024 Registration No. |
|
| July 19, 2024 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-3 (Form Type) REVELATION BIOSCIENCES, INC. |
|
| June 24, 2024 |
Exhibit 99.1 NOTICE OF EXERCISE To: Revelation Biosciences, Inc. (1) The undersigned hereby elects to purchase Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any. (2) Payment shall take the form of (check applicable box): [ ] in lawfu |
|
| June 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2024 REVELATION BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39603 84-3898466 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| June 18, 2024 |
Exhibit 23.01 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in this Registration Statement on Form S-8 of Revelation Biosciences, Inc. (the “Company”) of our report dated March 22, 2024 relating to the consolidated financial statements of Revelation Biosciences, Inc., as of and for the years ended December 31, 2023 and 2022, which includes an |
|
| June 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 REVELATION BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 84-3898466 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 4660 La Jolla Village Drive, Suite 100 San Diego, CA 92122 |
|
| June 18, 2024 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) REVELATION BIOSCIENCES, INC. |
|
| June 18, 2024 |
Exhibit 5.01 J.P. Galda & Co. Attorneys-at-Law 40 East Montgomery Avenue, LTW 220 Ardmore, Pennsylvania 19003 Telephone: 215-815-1534 June 18, 2024 Revelation Biosciences, Inc. 4660 La Jolla Village Drive, Suite 100 San Diego, California 92122 Ladies and Gentlemen: Re: Registration on Form S-8 We have acted as counsel to Revelation Biosciences, Inc., a corporation incorporated under the laws of th |
|
| May 16, 2024 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 REVELATION BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39603 84-3898466 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39603 REVELATION BIOSCIENCES, INC. |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2024 REVELATION BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39603 84-3898466 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 10, 2024 |
Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024 Exhibit 99.1 Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024 San Diego, CA – May 10, 2024 – Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today reported its three months ende |
|
| April 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| April 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| March 22, 2024 |
Exhibit 97 CLAWBACK POLICY (November 20, 2023) I. Purpose The Board of Directors (the “Board”) of Revelation Biosciences, Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to adopt this Clawback Policy (the "Policy"), which provides for the recovery of certain incentive compensation in the event of an Accounting Restatement (as defined below). This |
|
| March 22, 2024 |
Exhibit 99.1 Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023 San Diego, CA – March 22, 2024 – Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today reported its t |
|
| March 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K 1vavageord UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39603 REVELATION BIOSCIENCES, INC. |
|
| March 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2024 REVELATION BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39603 84-3898466 (State or Other Jurisdiction of Incorporation) (Commis |
|
| March 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2024 REVELATION BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39603 84-3898466 (State or Other Jurisdiction of Incorporation) (Commis |
|
| March 12, 2024 |
Gemini is a proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic, detoxified version of lipopolysaccharide (LPS). |
|
| March 12, 2024 |
Oral Presentation at the 29th International Conference on Advances in Critical Care Nephrology: AKI and CRRT - March 2024 Intravenous GeminiTM for Prevention of Acute Kidney Injury Prophylactic Administration of Gemini (intravenous PHAD®) Reduces Tissue Damage and Improves Kidney Function in a Rat Model of Bilateral Ischemic Reperfusion Induced Acute Kidney Injury (AKI) Presented by Robin Marsden, Senior Vice President, Biology Introduction Gemini is a proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic, detoxified version of lipopolysaccharide (LPS). |
|
| February 13, 2024 |
US76135L3096 / REVELATION BIOSCIENCES INC / Lind Global Fund II LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Revelation Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 76135L309 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designat |
|
| February 13, 2024 |
EX-99.1 2 exhibit99-1.htm JOINT FILING AGREEMENT BY AND AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock, par value $0.001 per share, of Revelation Biosciences, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to |
|
| February 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 05, 2024 REVELATION BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39603 84-3898466 (State or Other Jurisdiction of Incorporation) (Com |
|
| February 8, 2024 |
Form of Placement Agency Agreement dated February 1, 2024 EXHIBIT 10.1 PLACEMENT AGENCY AGREEMENT February 1, 2024 Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Revelation Biosciences, Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $6,183,450 of registered securities of the Co |
|
| February 8, 2024 |
Form of Warrant Agency Agreement with Continental Stock Transfer & Trust Co. dated February 5, 2024 EXHIBIT 4.1 Revelation Biosciences, Inc. and Continental Stock Transfer & Trust Company as Warrant Agent Warrant Agency Agreement Dated as of February 5, 2024 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of February 5, 2024 (“Agreement”), between Revelation Biosciences, Inc., a Delaware corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporati |
|
| February 8, 2024 |
Form of Class D Pre-Funded Warrant dated February 5, 2024 Exhibit 4.2 PRE-FUNDED COMMON STOCK PURCHASE WARRANT Revelation Biosciences, Inc. Warrant Shares: Initial Exercise Date: February 5, 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or aft |
|
| February 8, 2024 |
Form of Securities Purchase Agreement dated February 1, 2024 Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 1, 2024, between Revelation Biosciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and con |
|
| February 8, 2024 |
Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering Exhibit 99.2 Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering San Diego, CA – February 5, 2024 – Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced the closing on February 5, 2024 of its previously ann |
|
| February 8, 2024 |
Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering Exhibit 99.1 Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering San Diego, CA – February 1, 2024 – Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced the pricing of a public offering of 1,365,000 shares |
|
| February 8, 2024 |
Form of Class D Common Stock Warrant dated February 5, 2024 EXHIBIT 4.3 CLASS D COMMON STOCK PURCHASE WARRANT Revelation Biosciences, Inc. Warrant Shares: 2,730,000 Initial Exercise Date: February 5, 2024 CUSIP: 76135L143 ISIN: US76135L1439 THIS CLASS D COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, CEDE & CO. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the cond |
|
| February 2, 2024 |
Rule 424(b)(3) Commission File No. 333-276232 Rule 424(b)(3) Commission File No. 333-276232 PROSPECTUS REVELATION BIOSCIENCES, INC. 128,470 Shares of Common Stock 1,236,530 Pre-Funded Warrants to Purchase up to 1,236,530 Shares of Common Stock and up to 1,236,530 Shares of Common Stock Underlying the Pre-Funded Warrants 2,730,000 Class D Common Stock Warrants to Purchase up to 2,730,000 Shares of Common Stock and up to 2,730,000 Shares of Com |
|
| January 30, 2024 |
Developing innovative therapeutics to address unmet needs Corporate Presentation / January 2024 www. |
|
| January 30, 2024 |
Revelation Biosciences, Inc. 4660 La Jolla Village Drive San Diego, California 92122 Revelation Biosciences, Inc. 4660 La Jolla Village Drive San Diego, California 92122 January 30, 2024 Via EDGAR Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Attention: Cindy Polynice Laura Crotty Re: Revelation Biosciences, Inc. Registration Statement on Form S-1 Commission File No. 333-276232 Mesdames Polynice and Crotty: On behalf of Revelation Biosciences, Inc. (the |
|
| January 30, 2024 |
As filed with the U.S. Securities and Exchange Commission on January 30, 2024. As filed with the U.S. Securities and Exchange Commission on January 30, 2024. Registration No. 333-276232 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 REVELATION BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) DELAWARE (Jurisdiction of incorporation or organizati |
|
| January 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2024 REVELATION BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39603 84-3898466 (State or Other Jurisdiction of Incorporation) (Comm |
|
| January 29, 2024 |
J.P. Galda & Co. 40 Montgomery Avenue, LTW 220 Ardmore, Pennsylvania 19003 Telephone (215) 815-1534 J.P. Galda & Co. Attorneys-at-Law 40 Montgomery Avenue, LTW 220 Ardmore, Pennsylvania 19003 Telephone (215) 815-1534 January 29, 2024 Via EDGAR U.S. Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Attention: Cindy Polynice Laura Crotty Re: Revelation Biosciences, Inc. Registration Statement on Form S-1 File Number 333-276232 Mesdames Polynice and Crotty: Today Revelation B |
|
| January 29, 2024 |
Form of Placement Agency Agreement with Roth Capital Partners, LLC Exhibit 10.3 PLACEMENT AGENCY AGREEMENT , 2024 Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Revelation Biosciences, Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $ of registered securities of the Company, including, b |
|
| January 29, 2024 |
Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2024, between Revelation Biosciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions se |
|
| January 29, 2024 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) Revelation Biosciences, Inc. |
|
| January 29, 2024 |
Form of Class D Common Stock Warrant Exhibit 4.12 CLASS D COMMON STOCK PURCHASE WARRANT Revelation Biosciences, Inc. Warrant Shares: Initial Exercise Date: , 2024 THIS CLASS D COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date her |
|
| January 29, 2024 |
As filed with the U.S. Securities and Exchange Commission on January 29, 2024. As filed with the U.S. Securities and Exchange Commission on January 29, 2024. Registration No. 333-276232 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 REVELATION BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) DELAWARE (Jurisdiction of incorporation or organizati |
|
| January 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2024 REVELATION BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39603 84-3898466 (State or Other Jurisdiction of Incorporation) (Comm |
|
| January 23, 2024 |
Amendment to the Third Amended and Restated Certificate of Incorporation dated January 22, 2024 EXHIBIT 3.1 CERTIFICATE OF AMENDMENT to the THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION of REVELATION BIOSCIENCES, INC. REVELATION BIOSCIENCES, INC., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify as follows: FIRST: The name of the Corporation is Revelation Biosciences, Inc. The Corporation’s orig |
|
| January 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2024 REVELATION BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39603 84-3898466 (State or Other Jurisdiction of Incorporation) (Comm |
|
| January 3, 2024 |
REVB / Revelation Biosciences, Inc. / SABBY MANAGEMENT, LLC - REVB 13G 1.03.24 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 2, 2024 |
United States securities and exchange commission logo January 2, 2024 James Rolke Chief Executive Officer Revelation Biosciences, Inc. |
|
| December 22, 2023 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) Revelation Biosciences, Inc. |
|
| December 22, 2023 |
Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2024, between Revelation Biosciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions se |
|
| December 22, 2023 |
Form of New Pre-Funded Common Stock Warrant Exhibit 4.13 PRE-FUNDED COMMON STOCK PURCHASE WARRANT Revelation Biosciences, Inc. Warrant Shares: Initial Exercise Date: , 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the da |
|
| December 22, 2023 |
Exhibit 10.2 LOCK-UP AGREEMENT , 20 Revelation Biosciences, Inc. Roth Capital Partners, LLC, as placement agent in the Offering (as defined below) Re: Offering (as defined below) by Revelation Biosciences, Inc. (the “Company”) Ladies and Gentlemen: The undersigned irrevocably agrees with the Company that, from the date hereof until ninety (90) days following the closing of the Company’s offering o |
|
| December 22, 2023 |
Form of Warrant Agency Agreement with Continental Stock Transfer & Trust Co. Exhibit 4.14 Revelation Biosciences, Inc. and Continental Stock Transfer & Trust Company as Warrant Agent Warrant Agency Agreement Dated as of , 2024 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of , 2024 (“Agreement”), between Revelation Biosciences, Inc., a Delaware corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation (the “Warrant Ag |
|
| December 22, 2023 |
Form of Placement Agency Agreement with Roth Capital Partners, LLC Exhibit 10.3 PLACEMENT AGENCY AGREEMENT , 2024 Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Revelation Biosciences, Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $ of registered securities of the Company, including, b |
|
| December 22, 2023 |
Form of Class D Common Stock Warrant Exhibit 4.12 CLASS D COMMON STOCK PURCHASE WARRANT Revelation Biosciences, Inc. Warrant Shares: Initial Exercise Date: , 2024 THIS CLASS D COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date her |
|
| December 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| December 22, 2023 |
As filed with the U.S. Securities and Exchange Commission on December 22, 2023. As filed with the U.S. Securities and Exchange Commission on December 22, 2023. Registration No. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 REVELATION BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) DELAWARE (Jurisdiction of incorporation or organization) 2834 84-3898466 (Primary |
|
| December 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| November 13, 2023 |
Exhibit 99.1 Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2023 San Diego, CA – November 13, 2023 – Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today reported its three and nine |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 REVELATION BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39603 84-3898466 (State or Other Jurisdiction of Incorporation) (Com |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39603 REVELATION BIOSCIENCES, INC. |
|
| October 12, 2023 |
Developing innovative therapeutics to address unmet needs Corporate Presentation / October 2023 www. |
|
| October 12, 2023 |
Gemini Induces Pharmacologic Activity and Related Physiologic Changes in Multiple Preclinical Studies - Key Biomarker Activity Confirmed for Evaluation in Upcoming Phase 1 Study - San Diego, CA – October 12, 2023 – Revelation Biosciences Inc. |
|
| October 12, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2023 REVELATION BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39603 84-3898466 (State or Other Jurisdiction of Incorporation) (Comm |
|
| October 2, 2023 |
Revelation Biosciences Inc. Announces Appointment of Lakhmir Chawla, M.D. to Board of Directors Exhibit 99.1 Revelation Biosciences Inc. Announces Appointment of Lakhmir Chawla, M.D. to Board of Directors San Diego, CA –October 2, 2023 – Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today announced the appointment of Lakhmir Chaw |
|
| October 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2023 REVELATION BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39603 84-3898466 (State or Other Jurisdiction of Incorporation) (Co |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39603 REVELATION BIOSCIENCES, INC. |
|
| August 11, 2023 |
Exhibit 99.1 Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2023 San Diego, CA – August 11, 2023 – Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today reported its three and six mont |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 08, 2023 REVELATION BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39603 84-3898466 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 11, 2023 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) REVELATION BIOSCIENCES, INC. |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 REVELATION BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 84-3898466 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 4660 La Jolla Village Drive, Suite 100 San Diego, CA 92122 |
|
| August 11, 2023 |
J.P. Galda & Co. Attorneys-at-Law 40 East Montgomery Avenue, LTW 220 Ardmore, Pennsylvania 19003 Telephone: 215-815-1534 August 11, 2023 Revelation Biosciences, Inc. 4660 La Jolla Village Drive, Suite 100 San Diego, California 92122 Ladies and Gentlemen: Re: Registration on Form S-8 We have acted as counsel to Revelation Biosciences, Inc., a corporation incorporated under the laws of the State of |
|
| August 11, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2023 REVELATION BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39603 84-3898466 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 11, 2023 |
Exhibit 23.01 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in this Registration Statement on Form S-8 of Revelation Biosciences, Inc. (the “Company”) of our report dated March 30, 2023 (which includes an explanatory paragraph regarding the existence of substantial doubt about the Company’s ability to continue as a going concern), relating to |
|
| July 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2023 REVELATION BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39603 84-3898466 (State or Other Jurisdiction of Incorporation) (Commiss |
